Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;52(4):302-305.
doi: 10.1310/hpj5204-302.

Eteplirsen

Danial E Baker

Eteplirsen

Danial E Baker. Hosp Pharm. 2017 Apr.

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The April 2017 monograph topics are deflazacort, plecanatide, delafloxacin, oxymetazoline hydrochloride 1% cream, and betrixaban. The DUE is on plecanatide.

PubMed Disclaimer

Similar articles

  • Formulary Drug Review: Betrixaban.
    Baker DE. Baker DE. Hosp Pharm. 2018 Feb;53(1):29-37. doi: 10.1177/0018578717739397. Epub 2017 Nov 6. Hosp Pharm. 2018. PMID: 29434384 Free PMC article. Review.
  • Insulin Degludec/Liraglutide.
    Baker DE. Baker DE. Hosp Pharm. 2017 May;52(5):374-380. doi: 10.1177/0018578717715383. Epub 2017 May 1. Hosp Pharm. 2017. PMID: 28804155 Free PMC article. Review.
  • Sugammadex.
    Cada DJ, Levien TL, Baker DE. Cada DJ, et al. Hosp Pharm. 2016 Jul;51(7):585-96. doi: 10.1310/hpj5107-585. Hosp Pharm. 2016. PMID: 27559192 Free PMC article.
  • Daclizumab.
    Kim AP, Baker DE. Kim AP, et al. Hosp Pharm. 2016 Dec;51(11):928-939. doi: 10.1310/hpj5111-928. Hosp Pharm. 2016. PMID: 28057953 Free PMC article.
  • Formulary Drug Review: Ocrelizumab.
    Ali ZK, Baker DE. Ali ZK, et al. Hosp Pharm. 2017 Oct;52(9):599-606. doi: 10.1177/0018578717731733. Epub 2017 Sep 17. Hosp Pharm. 2017. PMID: 29276296 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Exondys 51 (eteplirsen) [prescribing information]. Cambridge, MA: Sarepta Therapeutics Inc; September 2016.
    1. Woodcock J. NDA approval letter: Exondys 51 (eteplirsen NDA 206488). US Food and Drug Administration website. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/206488Orig1.... Published September 19, 2019. Accessed September 19, 2019.
    1. Kole R, Krieg AM.. Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev. 2015; 87: 104– 107. - PubMed
    1. Mah JK. Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat. 2016; 12: 1795– 1807. - PMC - PubMed
    1. Miyatake S, Shimizu-Motohashi Y, Takeda S, Aoki Y.. Anti-inflammatory drugs for Duchenne muscular dystrophy: Focus on skeletal muscle-releasing factors. Drug Des Devel Ther. 2016; 10: 2745– 2758. - PMC - PubMed